Analysts have provided the following ratings for TCR2 Therapeutics TCRR within the last quarter:
|Bullish||Somewhat Bullish||Indifferent||Somewhat Bearish||Bearish|
According to 5 analyst offering 12-month price targets in the last 3 months, TCR2 Therapeutics has an average price target of $20.8 with a high of $31.00 and a low of $8.00.
Below is a summary of how these 5 analysts rated TCR2 Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the move negative analysts are on the stock
This current average represents a 40.23% increase from the previous average price target of $34.8.
Analyst Ratings: What Are They?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.